ClinicalTrials.gg
RecruitingNCT03357536Listeria-GENUpdated Sep 19, 2025

Genetic Susceptibility to Listeriosis

An interventional study of Human biological samples in Listeriosis, sponsored by Institut Pasteur. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Institut Pasteur · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Nov 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Sex
All
01

Study summary

Listeriosis is a rare, severe foodborne infection, responsible for severe invasive infections. It occurs in the great majority of cases in elderly patients and / or patients with comorbidities, with a deficit of innate or cellular immunity. Pregnancy is also a risk factor.

The Multicentric Observational NAtional Analysis of Listeriosis and Listeria (MONALISA) is an ongoing national case-control prospective study on listeriosis implemented since 2009 to study risk and prognosis factors for listeriosis. In this cohort, which enrolled 902 patients on 1 August 2014, 7% of patients with neurolisteriosis are under 40 years of age and have no identified risk factor. Genetic susceptibility is suspected in these patients. Genetic susceptibility could also explain the inconstant development of a neurolisteriosis or fetal infection, as well as the particular severity of some infections (death, foetal loss, neurological sequelae).

The aim of the study is to identify genetic susceptibility to Listeriosis.

Read the detailed description

Listeriosis is a rare, severe foodborne infection caused by the bacterium Listeria monocytogenes (Lm), responsible for severe invasive infections. It occurs in the great majority of cases in elderly patients and / or patients with comorbidities, with a deficit of innate or cellular immunity. Pregnancy is also a risk factor.

The Multicentric Observational NAtional Analysis of Listeriosis and Listeria (MONALISA) is an ongoing national case-control prospective study on listeriosis implemented since 2009 to study risk and prognosis factors for listeriosis. In this cohort, which enrolled 902 patients on 1 August 2014, 7% of patients with neurolisteriosis are under 40 years of age and have no identified risk factor. Genetic susceptibility is suspected in these patients. Genetic susceptibility could also explain the inconstant development of a neurolisteriosis or fetal infection, as well as the particular severity of some infections (death, foetal loss, neurological sequelae).

The analysis of the genetically transmitted vulnerability of Lm has not yet been studied, because of the lack of accessibility to prospective cohorts (and their DNA) for this rare and severe infection.

The aim of the study is to identify genetic susceptibility to Listeriosis that will optimize the patient care in terms of treatment and prevention.

02

Conditions studied

  • Listeriosis
03

In context

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for patients with Listeriosis :

  • Microbiologically documented Listeriosis (either a severe form of listeriosis, or an atypical form of listeriosis, or less than 40 years old and without any co-morbidity identified)
  • Affiliated or beneficiary of a social security system
  • Informed and written consent

Inclusion Criteria for volunteers related to patients with Listeriosis (after identifying a genetic susceptibility in the patient with Listeriosis) :

  • defined as father, mother, brother (s), sister (s), child (ren), grandparent (s), uncle (s), aunt (s), cousin (s), nephew (s), niece (s).
  • Affiliated or beneficiary of a social security system
  • Informed and written consent

Exclusion Criteria for volunteers related to patients with Listeriosis:

  • Inability to consent
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Patients with Listeriosis

    Patients with Listeriosis. Human biological samples : * Blood sample * Skin biopsy * Saliva

    Procedure: Human biological samples

  • Experimental
    Volunteers related with patients with Listeriosis

    Volunteers related with patients with Listeriosis. Human biological samples : * Blood sample * Skin biopsy * Saliva

    Procedure: Human biological samples

Interventions

  • ProcedureHuman biological samples

    * Blood sample * Skin biopsy * Saliva

06

What researchers measure

Primary outcomes

  1. Identification of a susceptibility factor associated with Listeriosis infection

    In patients with Listeriosis, the hypothesis that the identified genetic variation is the mutation responsible for the infection will be verified : * by verifying that it is not a listed polymorphism by sequencing genomic DNA controls * by verifiyng that family genetic segregation is compatible with clinical segregation * by verifying the function of the mutated protein in the patient's cell lines and / or fresh cells * by performing complementation experiments by transfecting the wild-type allele into the patient's cells

    Time frame: 10 years

Secondary outcomes

  1. Identification of a susceptibility factor associated with the most severe or atypical forms

    In patients with Listeriosis, the susceptibility factor associated with the most severe or atypical forms will be characterized : * By testing the response and production of cytokines involved in infection control. * By identifying chromosomal regions associated with the disease by a homozygosity mapping genetic study on multiplex and / or inbred families. * By sequencing the identified candidate genes.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2017 (actual). Primary completion is estimated for Nov 2027, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2017
First posted
Nov 30, 2017
StartActual
Nov 28, 2017
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03357536
Lead sponsor
Institut Pasteur
Responsible party
Sponsor
First posted
Nov 30, 2017
Start date
Nov 28, 2017
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Sep 19, 2025

Study contacts

Marc Lecuit
Contact
marc.lecuit@pasteur.fr
+33 1 40 61 34 20
Caroline Charlier-Woerther
Contact
caroline.charlier@pasteur.fr
+33 1 40 31 30 10
Marc Lecuit
study director · Institut Pasteur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion